Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.36 |
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 8/20 | 0.33 |
| ▸ | CDK9 | P50750 | 8/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | FLT1 | P17948 | 1/20 | 0.33 |
| ▸ | FLT4 | P35916 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 2/20 | 0.32 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | PGK1 | P00558 | 1/20 | 0.32 |
| ▸ | QPCT | Q16769 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2985854 | 0.97 | KDR (0.37) | KDRGSK3BSRCCCNT1CDK9 | |
| SCHEMBL2988529 | 0.94 | GSK3B (0.36) | KDRGSK3BCCNT1CDK9EGFR | |
| SCHEMBL2982546 | 0.92 | CDK9 (0.35) | KDRCCNT1CDK9EGFRFGFR1 | |
| SCHEMBL2997352 | 0.89 | CDK9 (0.40) | KDRGSK3BSRCCCNT1CDK9 | |
| SCHEMBL2992455 | 0.88 | CCNT1 (0.39) | SRCCCNT1CDK9CSF1R | |
| SCHEMBL2990280 | 0.87 | HRH4 (0.39) | KDRGSK3BSRCHRH4CCNT1 | |
| SCHEMBL2986599 | 0.87 | HTR4 (0.34) | CCNT1CDK9 | |
| SCHEMBL2988514 | 0.85 | CDK9 (0.41) | KDRGSK3BSRCCCNT1CDK9 | |
| SCHEMBL27714257 | 0.83 | IGF1R (0.34) | KDRGSK3BCCNT1CDK9FGFR1 | |
| SCHEMBL2990078 | 0.80 | CDK9 (0.38) | GSK3BCCNT1CDK9EGFRPGK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256141-A1 | NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2010-10-07 | — | — | US | disclosed |
| US-7786114-B2 | Bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2010-08-31 | — | — | US | disclosed |
| US-20080045561-A1 | Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-02-21 | — | — | US | disclosed |
| EP-1799691-A1 | NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006037875-A1 | NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045561-A1 | Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors | BRSK2, KSR2, CDK2 | KDR 637/4885GSK3B 438/4885SRC 229/4885 |
| US-20100256141-A1 | NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | BRSK2, KSR2, CDK2 | KDR 637/4885GSK3B 438/4885SRC 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.